Orthofix Medical Inc. (OFIX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XFRA 
The Schall Law Firm Is Probing Orthofix Medical Inc And Encourages Affected Investors To Join The Conversation
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Investigating Orthofix Medical Inc And Encourages Affected Investors To Participate In The Discussion
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Investigates Orthofix Medical Inc And Urges Affected Investors To Join The Conversation
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Orthofix Medical Inc. (OFIX) Q2 2024 Earnings Call Transcript
Orthofix Medical Inc. (NASDAQ:OFIX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Julie Dewey - Chief IR and Communications Officer Massimo Calafiore - President and CEO Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Ryan Zimmerman - BTIG Jason Wittes - ROTH MKM Operator Thank you for standing by. My name is Krista and I will be your conference operator today.
Orthofix (OFIX) Surpasses Q2 Earnings and Revenue Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to earnings of $0.02 per share a year ago.
The Schall Law Firm Investigates Orthofix Medical Inc And Urges Affected Investors To Join The Conversation
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Investigates Orthofix Medical Inc And Urges Affected Investors To Join The Conversation
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Investigates Orthofix Medical Inc And Urges Affected Investors To Join The Conversation
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Investigates Orthofix Medical Inc And Urges Affected Investors To Join The Conversation
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Investigates Orthofix Medical Inc And Urges Affected Investors To Join The Conversation
LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Investigates Orthofix Medical Inc And Urges Affected Investors To Join The Conversation
LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Investigating Orthofix Medical Inc And Encourages Affected Investors To Join The Conversation
LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
